Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials
Immuno-oncology (IO) has been an active area of oncology research. Following US FDA approval of the first immune checkpoint inhibitor (ICI), ipilimumab (human IgG1 k anti-CTLA-4 monoclonal antibody), in 2011, and of the first oncolytic virus, Imlygic (talimogene laherparepvec), in 2015, there has be...
Main Authors: | June Kyu Hwang, JinWoo Hong, Chae-Ok Yun |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2020-11-01
|
Series: | International Journal of Molecular Sciences |
Subjects: | |
Online Access: | https://www.mdpi.com/1422-0067/21/22/8627 |
Similar Items
-
Oncolytic Viruses and Immune Checkpoint Inhibitors: The “Hot” New Power Couple
by: Charlotte Lovatt, et al.
Published: (2023-08-01) -
The Present Status of Immuno-Oncolytic Viruses in the Treatment of Pancreatic Cancer
by: Scott D. Haller, et al.
Published: (2020-11-01) -
Combination therapy with oncolytic viruses and immune checkpoint inhibitors in head and neck squamous cell carcinomas: an approach of complementary advantages
by: Hui Dong, et al.
Published: (2023-01-01) -
Combination of immune checkpoint inhibitors with radiation therapy in cancer: A hammer breaking the wall of resistance
by: Veronika Voronova, et al.
Published: (2022-12-01) -
Treatment of HPV-Related Uterine Cervical Cancer with a Third-Generation Oncolytic Herpes Simplex Virus in Combination with an Immune Checkpoint Inhibitor
by: Masahiro Kagabu, et al.
Published: (2023-01-01)